Chad Rusthoven, MD
Radiation Oncology · Morehead City, NCNPI 1265758205
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,150 of the $3,258 with a category attached, or 96.7%. AstraZeneca accounts for 96.7% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $1085.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Visionrt, Inc.$80
- Zap Surgical Systems, Inc.$28
Across 28 payments — averaging $40,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- AbbVie$63K
What the payments were for
- Consulting fees$3,15097%
- Food & beverage$1083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $3,150 |
| Visionrt, Inc. | 1 | $80 |
| Zap Surgical Systems, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$3,150
How this compares
$3,258 in reported general payments places this provider in the 80th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 49 | $680 |
| Mometasone Furoate | 33 | $326 |
| Sucralfate | 24 | $270 |
| Dexamethasone | 12 | $119 |
| Ondansetron Hcl | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Morehead City
- Andrew WangChapel Hill$118K
- Volker StieberWinston Salem$99K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
- Michael ChanWinston Salem$32K
- John KirkpatrickDurham$29K
- John HeinzerlingCharlotte$29K
- Brian CzitoDurham$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.